Prolevi Bio

Developing the first effective treatment for hypothyroidism

Summary

  • A disease affecting more than 750M – with 80% patients dissatisfied.
  • Current treatments are unable to follow healthy thyroid gland release cycles.
  • ProLevi develops a modified release thyroid hormone formulation mimicking the circadian rhythm.

Hypothyroidism

Thyroid hormone — Control development & metabolism

Liothyronine (LT3), API- T3, active hormone
Levothyroxine (LT4), API- T4 inactive hormone

Thyroid hormone — Control development & metabolism

Hypothyroidism affects 10% of the global population. 70-80% patients are dissatisfied with current treatment (Hegedus L, Nat Rev Endo,2022). For 15-20% of all patients, T4 is ineffective because of underlying genetics or unidentified mechanisms.

T3, the active hormone controls cell metabolism, heart rate, body temperature, peristalsis, muscle contractions and apoptosis. Symptoms of hypothyroidism include fatigue, weight gain, cognitive decline, increase in cholesterol levels, dry skin and hair loss.

Prolevi deploys hormonal formulations that synchronizes with natural circadian rhythm for personalized patient treatment. We improve long term side effects, overdosing and patient compliance with our platform patent- pending drug formulations.

Our solution
Thyroid care in Sweden

Experience fatigue

Increased Anxiety

Weight gain

Sleep deprivation

Memory loss

Lifestyle impediment

80% of patients are dissatisfied
with current treatment*

28% treated with antidepressants (Sweden- SE)**
1 in 10 too ill to work- 600M €/yr loss (SE)**

0

millions affected

0

dissatisfied*

0

millions report poor life quality

0

millions administered clinically ineffective treatment (non-responders)

Thyroid hormone levels follow the circadian rhythm

Keisuke Ikegami et. al, 2019, Nature Rev Endo

J Clin Endocrinol Metab 93: 2300–2306, 2008

T3 and TSH levels follow the circadian clock

Problem with current treatments

  • Failure to mimic T3 natural release cycles
  • T3 today is immediate release with short half life
  • Poor patient compliance (T3 dosing thrice a day)
  • Overdosing and long-term side-effects

Our solution

A modified release thyroid hormone formulation mimicking the circadian rhythm

Intellectual Property

Our team

Sahil Gupta, CEO,
Founder

more

Sahil Gupta has a PhD from Goethe University Frankfurt with over 10 years of R&D experience in life sciences, immunology, and genetic engineering. Sahil is involved with overall company management and is lead on technical development and compliance.

Daniel Bar-Shalom, Head of Formulation, Founder

more

Daniel is Associate Professor at University of Copenhagen with more than 4 decades of experience in pharmaceutical products and inventor of more than 100 patents. Among other things, he is the inventor of the Egalet® technology, possibly the first to propose injection-moulding to produce oral controlled release dosage forms and to implement it in practice. He is also the inventor of the Parvulet® technology, a carrier of multiparticulate controlled release approaches. His activities have resulted in several marketed products and technologies. Daniel is Prolevi’s lead on the formulations, drug delivery and designs.

Lars Moberg, Chairman,
Partner

more

Lars Moberg has Masters in business administration from Lund University and CEO of Ekonomihuset Moberg AB, Malmö since 1991. Lars is Prolevi’s company chairman and is responsible for financial accounting. 

Company vision

Prolevi’s long term vision is to treat metabolic disorders deploying our platform patent pending technology. We personalize the formulations in synergy with circadian rhythm.

Prolevi will initially focus on bringing treatment to hypothyroid patients. 90% of patients, largely women remain dissatisfied and ignored with the current treatment. They suffer from broad symptoms despite normal hormone blood levels with existing therapy. This is due to lack of reliable tests, non-effective treatment and unstandardized worldwide screening (that should include fT3, fT4, rT3, T3, T4, and TSH). Prolevi’s solution ensures personalized therapy based on patient’s baseline characteristics.

Contact us

c/o Ekonomihuset Moberg AB
Geijersgatan 4 B 216 18 Limhamn
Sweden

Email
Phone
Open in a map